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Abstract
Evodiamine, an alkaloid extracted from the dried unripe fruit of the tree Evodia rutaecarpa Bentham (Rutaceae), reduces
obesity and insulin resistance in obese/diabetic mice; however, the mechanism underlying the effect of evodiamine on
insulin resistance is unknown. This study investigated the effect of evodiamine on signal transduction relating to insulin
resistance using obese/diabetic KK-Ay mice and an in vitro adipocyte culture. There is a significant decrease in the
mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in
KK-Ay mice treated with evodiamine, in which glucose tolerance is improved. In addition, reduction of insulin receptor
substrate 1 (IRS1) serine phosphorylation, an indicator of insulin resistance, was detected in their WAT, suggesting
suppression of the negative feedback loop from S6K to IRS1. As well as the stimulation of IRS1 and Akt serine
phosphorylation, insulin-stimulated phosphorylation of mTOR and S6K is time-dependent in 3T3-L1 adipocytes, whereas
evodiamine does not affect their phosphorylation except for an inhibitory effect on mTOR phosphorylation. Moreover,
evodiamine inhibits the insulin-stimulated phosphorylation of mTOR and S6K, leading to down-regulation of IRS1 serine
phosphorylation in the adipocytes. Evodiamine also stimulates phosphorylation of AMP-activated protein kinase (AMPK), an
important regulator of energy metabolism, which may cause down-regulation of mTOR signaling in adipocytes. A similar
effect on AMPK, mTOR and IRS1 phosphorylation was found in adipocytes treated with rosiglitazone. These results suggest
evodiamine improves glucose tolerance and prevents the progress of insulin resistance associated with obese/diabetic
states, at least in part, through inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes.
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Introduction
The increased availability of food in Western countries and in
Japan has augmented the prevalence of obesity and insulin
resistance, which are central in the development of metabolic
syndrome [1]. High fat intake is considered to be the major cause
of metabolic abnormalities due to overnutrition. Adipose tissue is
responsible for the majority of fat metabolism affecting largely
glucose metabolism and insulin sensitivity under the control of
various hormones and cytokines [2]. Nutrient overload increases
serum insulin levels, which stimulates uptake of free fatty acids
(FFAs) and glucose into adipocytes mainly in white adipose tissue
(WAT), where excess energy is stored in the form of triglycerides.
When this energy storage system is active, increases in the number
and size of adipocytes are required for additional fat deposition in
WAT, causing excessive growth of adipose tissue leading to obesity
[3]. Elevated levels of serum insulin as well as non-esterified FFAs
in the obese state decrease insulin sensitivity and increase insulin
resistance in metabolic tissues, including liver, muscle and adipose
tissue, leading to type 2 diabetes mellitus. Regulation of WAT is a
potential strategy for the treatment of obesity and for improve-
ment of insulin resistance. Brown adipose tissue (BAT) is
specialized for thermogenesis through the function of uncoupling
protein 1 (UCP1) located in the mitochondria [4,5]. Because of
UCP1, which dissipates caloric energy as heat, BAT has an
important role in preventing obesity, as shown in our earlier study
using UCP1-knockout mice [6]. It was found recently that
functional BAT, despite its reduction with age, exists in adult
humans and its level is correlated inversely to the degree of
adiposity [7,8]. These findings have accelerated basic and clinical
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studies on the stimulation of BAT formation and activity as a
potential therapeutic target against obesity and insulin resistance
[9]; however, an alternative strategy independent of UCP1
thermogenesis is needed for BAT-negative individuals.
Insulin signaling is implicated in the regulation of adipocyte
biology. Many of the metabolic and anti-apoptotic effects of
insulin are mediated by the signaling pathway beginning from
phosphorylation and activation of insulin/insulin-like growth
factor I receptors, which results in tyrosine phosphorylation of
the insulin receptor substrate 1 (IRS1) [10]. Activation of
phosphatidylinositol 3-kinase (PI3K) and protein kinase B/Akt
by the IRS1 protein appears to be important in the mechanism of
glucose uptake in adipocytes and muscle cells. In addition, insulin
signaling is intimately linked to the nutrient-responsive mamma-
lian target of rapamycin (mTOR) signaling pathway via activation
of Akt [11,12]. The activation of mTOR phosphorylates its
downstream protein ribosomal S6 protein kinase (S6K), partici-
pating in several processes including protein synthesis and
proliferation [12,13]. It became apparent that serine phosphory-
lation of IRS1 reduces the ability of IRS1 to activate PI3K
[10–12]. In diet-induced obesity, overactivation of mTOR-S6K
signaling favors expansion of the WAT mass, leading to insulin
resistance of adipocytes through elevated serine phosphorylation of
IRS1. Mice deficient of S6K are protected against diet-induced
obesity and show enhanced insulin sensitivity owing to the loss of
the negative feedback loop from S6K to IRS1 [14,15]. These
findings suggest further development of interventions targeting
mTOR-S6K signaling for the treatment and prevention of obesity
and insulin resistance.
Evodiamine, an alkaloid extracted from the dried unripe fruit of
Evodia rutaecarpa Bentham (Rutaceae), has been used for many
years as a traditional Chinese herbal medicine for the treatment of
pain, vomiting and pyresis. Evodiamine has a wide variety of
bioactivity with antinociceptive, anti-obesity, vasodilatory, anti-
tumor and anti-inflammatory effects [16–20]. We found evodia-
mine decreases diet-induced obesity and glucose intolerance in a
UCP1-independent manner in mice [21]. We showed that
evodiamine increases phosphorylation of extracellular signal-
regulated kinase (ERK) and reduces the expression of transcription
factors such as PPARc in pre-adipocytes, strongly inhibiting their
differentiation into mature adipocytes. It was shown recently that
evodiamine improves insulin resistance and fat accumulation in
obese/diabetic db/db mice [22]. However, the mechanisms
underlying the effects of evodiamine on glucose tolerance and
insulin resistance are not known. This study used obese/diabetic
mice and adipocyte culture in vitro to investigate how evodiamine
affects glucose tolerance and insulin resistance, especially from the
viewpoint of signal transduction, including the mTOR-S6K
signaling pathway.
Results
Effects of evodiamine on metabolic phenotypes in
obese/diabetic KK-Ay mice
We examined the effects of evodiamine on the metabolic
phenotypes associated with obese/diabetic states in KK-Ay mice.
When mice were treated daily with evodiamine or vehicle (control)
for one week, a significant decrease in body weight (BW) gain, but
not in food intake, was found in the evodiamine group compared
to the control group (Figs. 1A, B). As shown in Table 1, there was a
significant reduction in tissue mass in several white fat depots,
including inguinal white adipose tissue (IWAT) and retroperito-
neal WAT (RWAT), in evodiamine-treated mice. There was no
difference in liver weight between the two groups (Table 1). The
same amount of glucose was fed to each group (Fig. 1C) but insulin
levels were significantly lower in the evodiamine group compared
to the control group (Fig. 1D), suggesting increased insulin
sensitivity. Moreover, glucose intolerance (measured by an
intraperitoneal (i.p.) glucose tolerance test) decreased in the
evodiamine group compared to the control group (Fig. 1E).
Histological analysis showed decreased trends of adipocyte size in
WATs of the evodiamine group compared to the control group
(RWAT, 37376226 mm2 and 35036303 mm2; gonadal WAT
(GWAT), 18456205 mm2 and 14036152 mm2; IWAT,
41126592 mm2 and 38446308 mm2 in the control and evodia-
mine group, respectively; Fig. 2).
Evodiamine attenuates mTOR-S6K signaling and
down-regulates IRS1 serine phosphorylation in WAT of
obese/diabetic KK-Ay mice
We examined the effects of evodiamine on the signaling of
mTOR and IRS1 in the obese/diabetic mice because attenuated
phosphorylation of Akt, an upstream kinase for mTOR, is present
in the WAT of the evodiamine-treated mice, as reported [21].
There was no difference in mTOR Ser2448 phosphorylation in
RWAT between the evodiamine and control groups (Fig. S1A in
File S1) but there was a significant reduction of its level in IWAT
of KK-Ay mice treated with evodiamine compared to the control
group (Fig. 3A). There was a reduction in mTOR phosphorylation
also in the WAT of UCP1-KO mice treated with evodiamine
compared to the control group (Fig. S2A in File S1). There was no
effect of evodiamine on mTOR phosphorylation or UCP1 protein
level in the BAT of KK-Ay mice (Fig. S3 in File S1). Moreover,
there were decreases in S6K Thr389 phosphorylation in IWAT
and RWAT of evodiamine-treated mice (Fig. 3B and Fig. S1B in
File S1). Similar to the results for the WAT of UCP1-KO mice
treated with evodiamine (Figs. S2B, C in File S1), phosphorylation
of Akt Ser473 and IRS1 Ser636/639 in the IWAT of KK-Ay mice
was significantly lower (54% and 12% of the control, respectively)
in the evodiamine group compared to the vehicle group (Figs. 3C,
D) and phosphorylation of IRS1 Tyr612 and PDK1 Ser241 was
not different between the two groups (Figs. 3D, E). There were
significant decreases in the Akt and IRS1 serine phosphorylation
in the RWAT of mice treated with evodiamine compared to the
vehicle control (Figs. S1C, D in File S1). Although evodiamine
administration reduces mTOR phosphorylation in liver, the
phosphorylation levels of S6K, Akt and IRS1 were not different
between the evodiamine and control groups (Fig. 4). Likewise,
there were no differences in the phosphorylation levels of mTOR,
S6K, Akt and IRS1 in gastrocnemius muscle (GM) between the
evodiamine and control groups (Figs. S4A–D in File S1).
Evodiamine inhibits insulin-stimulated phosphorylation
of mTOR and S6K, reducing IRS1 serine phosphorylation
in 3T3-L1 adipocytes
To assess the direct effects of evodiamine on adipocytes, we
examined the effects of insulin and evodiamine on stimulation of
the mTOR-S6K signaling pathway using differentiated 3T3-L1
adipocytes. As well as the stimulation of IRS1 and Akt
phosphorylation, insulin-stimulated phosphorylation of mTOR
and S6K was time-dependent; however, evodiamine had little
effect on their phosphorylation (Fig. 5). Insulin, but not
evodiamine, stimulated ERK phosphorylation transiently in
mature adipocytes. This was in contrast to the effect of evodiamine
in 3T3-L1 pre-adipocytes, in which this compound markedly
increased ERK phosphorylation (Fig. S5 in File S1). In the
presence of insulin stimulation, evodiamine seemed to suppress the
Effect of Evodiamine on mTOR-S6K Signaling
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phosphorylation of mTOR, S6K, IRS1 and Akt, except for ERK
phosphorylation in adipocytes (Fig. 6), although evodiamine did
not affect glucose uptake in adipocytes (Fig. 7). Insulin-induced
serine phosphorylation of Akt and IRS1 was suppressed by
evodiamine in pre-adipocytes (Fig. S5 in File S1). We evaluated
the effects of insulin and evodiamine on phosphorylation of these
molecules in adipocytes. As shown in Figures 8A–E, insulin
markedly increased phosphorylation of mTOR (1.8-fold), S6K
(10.3-fold), IRS1 (26.1-fold), Akt (7.3-fold) and ERK (5.6-fold) in
3T3-L1 adipocytes compared to the control, whereas evodiamine
had no significant effect on phosphorylation of these signaling
molecules, except for an inhibitory effect on mTOR phosphory-
lation. By contrast, evodiamine suppressed insulin-stimulated
phosphorylation of mTOR, S6K and IRS1 in adipocytes
significantly (Figs. 8A–C). Evodiamine did not significantly affect
the levels of insulin-stimulated Akt or ERK phosphorylation in
adipocytes (Figs. 8D, E), although their phosphorylation was
affected considerably by evodiamine in pre-adipocytes; i.e. Akt
phosphorylation was inhibited but ERK phosphorylation was
enhanced (Fig. S5 in File S1) [21].
We examined the effects of rosiglitazone, an anti-diabetic
compound, on the phosphorylation of these signaling molecules
compared to the effects of insulin and evodiamine in adipocytes.
Similar to evodiamine, rosiglitazone alone did not affect
phosphorylation of S6K, IRS1, Akt and ERK (except mTOR)
in the cells but, like evodiamine, rosiglitazone suppressed insulin-
stimulated phosphorylation of mTOR and IRS1 in adipocytes
significantly (Figs. 8A, C), although its effect on S6K phosphor-
ylation in insulin-stimulated cells did not reach significance
(Fig. 8B). There was no significant effect of rosiglitazone on
insulin-stimulated Akt or ERK phosphorylation in adipocytes
(Figs. 8D, E).
Evodiamine stimulates phosphorylation of
AMP-activated protein kinase (AMPK) in 3T3-L1
adipocytes and WAT
From the results in Figures 8D–E, Akt and ERK may not be the
upstream effectors for mTOR-S6K signaling in mature adipocytes
stimulated by evodiamine. So, we finally examined an involvement
of AMPK in the mechanism by which evodiamine affects mTOR
signaling pathway, because its phosphorylation is negatively
regulated by the activity of AMPK, which regulates various
cellular processes including glucose and lipid metabolism [22,23].
As well as rosiglitazone, evodiamine significantly stimulated
AMPK Thr172 phosphorylation (1.9-fold) in 3T3-L1 adipocytes
compared to the control, whereas insulin had no effect on its
phosphorylation (Fig. 8F). Significant increaes in AMPK phos-
phorylation were also detected in the WAT and liver, but not in
gastrocnemius muscle (GM), of KK-Ay mice treated with
evodiamine compared to the vehicle control (Figs. 9A–C),
supporting the decreases of mTOR phosphorylation in these
tissues (Figs. 3A and 4A).
Discussion
Evodiamine is a multipotent compound that has a wide variety
of bioactivities, such as anti-obesity and anti-tumor effects [17,19].
Earlier, we reported that a dietary supplementation of evodiamine
inhibited adipocyte differentiation and several obesity-associated
phenotypes, such as insulin resistance in mice lacking UCP1
thermogenesis, indicating that UCP1-independent roles of this
compound improve health under conditions of excess caloric
intake [21]. Although indirect calorimetric analysis did not detect
the effect of evodiamine on energy expenditure, a precise analysis
of respiratory quotient (RQ) values indicated that a higher
frequency of higher RQ values was present in evodiamine-injected
mice compared to vehicle-injected animals. This indicates that
Figure 1. Effects of evodiamine on body weight, food intake, blood parameters and glucose tolerance in KK-Ay mice. Eight-weeks old
female KK-Ay mice were injected i.p. daily with evodiamine (3 mg/kg body weight) or vehicle for 1 week. A, Body weight gain; B, food intake; C, fed
glucose level; D, insulin level; E, IPGTT. After starvation for 17 h, mice were injected i.p. with glucose (1.5 mg/g body weight). Data are expressed as
mean6SEM; n = 14 and 13 for body weight gain and food intake; n = 8 each for glucose and insulin levels; n = 9 and 8 for IPGTT, in vehicle and
evodiamine groups, respectively. *p,0.05, ***p,0.001 vs. vehicle group.
doi:10.1371/journal.pone.0083264.g001
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evodiamine affects glucose homeostasis in the whole body (Fig. S6
in File S1). We also detected the effect of evodiamine on glucose
tolerance and insulin sensitivity in obese/diabetic KK-Ay mice, in
which decreases in BW gain and WAT mass were observed in the
evodiamine-treated KK-Ay mice compared to the vehicle control.
These results were consistent with the Bak’s study that evodiamine
prevented BW gain and insulin resistance in db/db mice [24].
Reduced fat accumulation in several depots of WAT might
contribute to the improvement of insulin sensitivity in the obese/
diabetic mice treated with evodiamine, because hypertrophy of
WATs is known to cause the decrease in insulin sensitivity in
animals.
The recent advance in understanding the role of the mTOR-
S6K signaling pathway is of great interest in relation to the effects
of evodiamine, because this signaling pathway is activated in
response to growth factors, insulin or nutrients such as glucose and
amino acids [12,14] and its increased activity leads to serine
phosphorylation of IRS1, creating a negative feedback loop to
insulin signaling that attenuates insulin sensitivity [14,15]. As
expected, there is a significant decrease in phosphorylation of S6K
in the WATs of evodiamine-treated KK-Ay mice. This down-
regulation of S6K activity appears to lead to reduced serine
phosphorylation of IRS1 in tissues, contributing to the improve-
ment of insulin sensitivity in KK-Ay mice treated with evodiamine.
Akt is also a key molecule for the intracellular signal cascade in the
regulation of many cellular activities, including growth, glucose
metabolism and adipogenesis [25,26]. Akt activity is regulated by
various pathways and insulin signaling via IRS1 and PDK1
[11,12]. IRS1 protein contains multiple sites for tyrosine
phosphorylation and both Tyr612 and Tyr632 are important for
IRS1 to fully activate PI3K and mediate translocation of GLUT4
in response to insulin in adipocytes [27]. PDK1 may also stimulate
GLUT4 translocation via atypical protein kinase C (PKC)
activation without Akt activation, because PDK1 phosphorylates
the PKC isoforms in a PI3K-dependent manner [28] and glucose
uptake can be regulated through the Akt-independent PI3K-PKC
pathway in adipocytes [29,30]. In the present study, there was a
significant decrease in Akt phosphorylation in WATs of evodia-
mine-treated KK-Ay mice compared to the vehicle control, which
is similar to the result in mice fed an evodiamine diet [21].
Nevertheless, glucose metabolism was improved in these evodia-
mine-treated mice. Moreover, evodiamine did not significantly
affect Akt phosphorylation or glucose uptake in adipocytes in vitro.
So, the contribution of decreased Akt phosphorylation in WATs to
the regulation of glucose uptake may be little in the evodiamine-
treated mice. Because phosphorylation of IRS1 Tyr612 and PDK1
Ser241 in the WAT was not changed by treatment with
evodiamine (Fig. 3), the decrease in Akt phosphorylation could
have been induced by signaling pathways other than the main
pathway of insulin signaling.
mTOR is the catalytic subunit of complexes mTORC1 and
mTORC2. Akt stimulates mTORC1 activity but, at the same
time, is a target of mTORC2 signaling [12]. So, the decrease in
Akt phosphorylation could be mediated by reduction of mTORC2
activity. The meaning of this down-regulation of Akt phosphor-
ylation in WATs is not clear, but its reduction might have
contributed to suppression of adipocyte differentiation, because
Figure 2. Histological analysis of BAT, RWAT, GWAT, IWAT and
liver in KK-Ay mice treated with evodiamine. Tissue samples were
collected from the mice treated with evodiamine for 7 days. Tissue
sections of brown adipose tissue (BAT), retroperitoneal (RWAT), gonadal
(GWAT), inguinal white adipose tissues (IWAT) and liver were stained
with hematoxylin and eosin.
doi:10.1371/journal.pone.0083264.g002
Table 1. Effect of evodiamine on tissue weight in KK-Ay mice.
Vehicle (n = 5) Evodiamine (n = 5) p
Body weight (g) 38.061.2 37.360.5 0.6001
Tissue weight (mg)
BAT 251625 236616 0.6305
IWAT 598629 467640 0.0300
GWAT 15846145 1283634 0.0786
RWAT 175610 133613 0.0372
MWAT 10176122 911623 0.4196
Kidney 17467 17966 0.5901
Liver 1901654 1862680 0.6979
Pancreas 330621 362617 0.2740
Heart 14662 16168 0.1163
Spleen 10169 8467 0.1722
Female 8-weeks old KK-Ay mice were injected i.p. daily with evodiamine (3 mg/kg
body weight) or vehicle control. After 1 week, non-fasting samples of tissues and
blood were collected. The left pads of inguinal (IWAT), gonadal (GWAT) and
retroperitoneal (RWAT) white adipose tissues were used to measure tissue weight.
BAT, brown adipose tissue; MWAT, mesenteric WAT.
doi:10.1371/journal.pone.0083264.t001
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adipogenesis is blocked in cultured cells or mice lacking Akt [26].
The insulin-stimlated Akt phosphorylation is attenuated by
evodiamine in pre-adipocytes but not in mature adipocytes.
Because the basal phosphorylation level of Akt is much higher in
pre-adipocytes than in mature adipocytes, it is possible that the
decreased level of Akt phosphorylation in WATs of mice treated
with evodiamine was owing to its reduction in pre-adipocytes,
rather than in mature adipocytes, existing in the depots. It is also
possible that reduction of mTORC2 activity might contribute to
the improvement of glucose tolerance in the evodiamine-treated
KK-Ay mice, as glucose uptake into WAT is increased in mice
with whole-body deletion of Rictor, the mTORC2 subunit,
whereas disruption of mTORC2 in liver causes glucose intoler-
ance [31]. Chronic treatment (2–4 weeks) with rapamycin, the
mTOR inhibitor, causes glucose intolerance and insulin resistance
in mice [31,32] but evodiamine appears not to be included,
because administration of this compound for 2 months improved
glucose tolerance and insulin resistance associated with diet-
induced obesity in mice [21], in which phosphorylation levels of
Figure 3. Effect of evodiamine on the mTOR-S6K signaling in
the inguinal WAT (IWAT) of mice treated with evodiamine.
Western blot analysis for mTOR (A), S6K (B), Akt (C), IRS1 (D) and PDK1
(E) were done with tissue lysates (30 mg protein) of IWAT from the
KK-Ay mice treated with evodiamine for 7 days. Phosphorylation levels
of mTOR Ser2448, S6K Thr389, Akt Ser473, IRS1 Tyr612 and Ser636/639,
and PDK1 Ser241 were normalized to the total level of each protein.
Data are expressed as mean6SEM (n = 5). *p,0.05, **p,0.01 vs. vehicle
group.
doi:10.1371/journal.pone.0083264.g003
Figure 4. Effect of evodiamine on the mTOR-S6K signaling in
the liver of mice treated with evodiamine. Western blot analysis
for mTOR (A), S6K (B), Akt (C) and IRS1 (D) were done with tissue lysates
(30–50 mg protein) of liver from the KK-Ay mice treated with
evodiamine for 7 days. Phosphorylation levels of mTOR Ser2448, S6K
Thr389, Akt Ser473 and IRS1 Ser636/639 were normalized to the total
level of each protein. Data are expressed as mean6SEM (n = 5).
**p,0.01 vs. vehicle group.
doi:10.1371/journal.pone.0083264.g004
Figure 5. Effect of evodiamine and insulin on the mTOR-S6K
signaling in differentiated adipocytes. After 3T3-L1 pre-adipocytes
were differentiated into mature adipocytes, the cells were maintained in
DMEM for 4 h and then stimulated by 20 nM insulin or 20 mM
evodiamine for the indicated length of time. The cell lysates (15–
30 mg protein) were analyzed for phosphorylation of mTOR Ser2448,
S6K Thr389, IRS1 Ser636/639, Akt Ser473 and ERK Thr202/Tyr204 by
Western blot analysis. Representative images of two independent
experiments are shown.
doi:10.1371/journal.pone.0083264.g005
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mTOR and IRS1 were decreased in evodiamine-treated WAT
(Fig. S2 in File S1). Likewise, mTORC1 activity appears to be
attenuated in the WATs of KK-Ay mice treated with evodiamine,
because the phosphorylation of S6K, a target of mTORC1
signaling, is reduced considerably in adipose tissues, which blocks
serine phosphorylation of IRS1. Similar effects of evodiamine on
mTOR-S6K signaling were confirmed in adipocytes in vitro. In
contrast to the insulin effects that stimulated serine phosphoryla-
tion of IRS1 and Akt as well as activation of mTOR-S6K
signaling, evodiamine alone does not affect these molecules except
for the inhibitory effect on mTOR phosphorylation in adipocytes.
However, evodiamine inhibited insulin-stimulated phosphoryla-
tion of mTOR and S6K, leading to suppression of IRS1 serine
phosphorylation in adipocytes, suggesting evodiamine acts to
improve insulin resistance by repressing activation of mTOR-S6K
signaling by insulin.
AMPK is a major cellular energy sensor controlling glucose and
lipid metabolism [22,23]. AMPK is activated in response to a
variety of stimuli, including metabolic stress that generates an
increase in the AMP/ATP ratio. Genetic and pharmacologic
studies demonstrated that AMPK is required for maintaining
glucose homeostasis [33]. Therefore, AMPK is now considered to
be a potential pharmacologic target for improving insulin
resistance, diabetes and metabolic syndrome. Ching et al. have
recently reported that evodiamine increased AMPK phosphory-
lation in endothelial cells [34]. In the present study, we found that
evodiame significantly stimulated AMPK phosphorylation in
mature adipocyte culture and in WAT of KK-Ay mice. The
increased phosphorylation of AMPK was also detected in liver in a
lesser extent, but not in skeletal muscle, in the evodiamine-treated
KK-Ay mice compared to the vehicle control. AMPK down-
regultes mTOR signaling pathway via phosphorylation of
tuberous sclerosis complex 2, which inhibits cell growth [12,35].
Therefore, it is plausible that evodiamine inhibits mTOR-S6K
signaling through AMPK phosphorylation in adipocytes. Because
increased AMPK phosphorylation and decreased mTOR phos-
phorylation were also detected in liver, but not in skeletal muscle,
of the evodiamine-treated mice, evodiamine might affect glucose
metabolism and insulin sensitivity in various tissues including
WAT and liver.
The anti-diabetic compound rosiglitazone has effects similar to
those of evodiamine on AMPK phosphorylation and insulin-
stimulated phosphorylation of mTOR and IRS1 in adipocytes,
although the effects of these two compounds on adipogenesis are
opposite; i.e. evodiamine inhibits but rosiglitazone stimulates the
cellular process [21,22]. It is noteworthy that the difference
between adipocytes and pre-adipocytes in responsiveness to
evodiamine, as indicated from the results of ERK and Akt
phosphorylation, suggests a change in the mode of evodiamine
action corresponding to the differentiation of pre-adipocytes into
mature adipocytes. So, evodiamine might exhibit its improved
effects against obesity and insulin resistance in different modes of
action in pre-adipocytes and adipocytes.
Our data suggest evodiamine improves glucose tolerance and
prevents progress of insulin resistance associated with obese/
diabetic states, at least in part, through AMPK activation followed
by inhibition of mTOR-S6K signaling and IRS1 serine phos-
phorylation in adipocytes. The anti-obesity effect of evodiamine
may also contribute indirectly to prevention against insulin
resistance. Considering that inhibition of mTOR-S6K signaling
has attracted a great deal of attention in connection with health
and longevity [12,36,37], evodiamine might be a unique
compound able to combat obesity and age-related diseases;
however, the effects of evodiamine on energy metabolism in other
metabolic tissues remain to be clarified.
Methods
Ethics statement
This study was performed in strict accordance with the
recommendations in Fundamental Guidelines for Proper Conduct
of Animal Experiment and Related Activities in Academic
Research Institutions under the jurisdiction of the Ministry of
Education, Culture, Sports, Science and Technology, Japan. The
protocol was approved by the Institutional Animal Care and Use
Committee in Chubu University (approval number: 2310039 and
2410003).
Figure 6. Effect of evodiamine on the insulin-stimulated
activation of mTOR-S6K signaling in differentiated adipocytes.
After 3T3-L1 pre-adipocytes were differentiated into mature adipocytes,
the cells were maintained in DMEM for 4 h and then stimulated by
20 nM insulin with or without 20 mM evodiamine for the indicated
length of time. The cell lysates (15–30 mg protein) were analyzed for
phosphorylation of mTOR Ser2448, S6K Thr389, IRS1 Ser636/639, Akt
Ser473 and ERK Thr202/Tyr204 by Western blot analysis. Representative
images of two independent experiments are shown.
doi:10.1371/journal.pone.0083264.g006
Figure 7. Effect of evodiamine and insulin on glucose uptake in
differentiated adipocytes. After 3T3-L1 pre-adipocytes were differ-
entiated into mature adipocytes, the cells were maintained in DMEM for
6 h and then stimulated by 20 nM insulin or 20 mM evodiamine alone,
or in combination with insulin and evodiamine for 40 min and with
1 mM 2DG for the last 20 min. The 2DG6P content in each cell sample
was measured by using glucose uptake colorimetric assay kit. Data are
expressed as mean6SEM (n = 3–4). ***p,0.001 vs. control group
without stimulation.
doi:10.1371/journal.pone.0083264.g007
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Experimental animals
KK-Ay mice were obtained from CLEA Japan, Inc. and
maintained at 2361uC under artificial lighting for 12 h/day and
provided a standard chow (11.6% kcal from fat; Diet no. CE-2,
CLEA Japan, Inc.) and tap water ad libitum. Eight-weeks old female
mice were administered evodiamine by i.p. injection (3 mg/kg
BW, KISIDA CHEMICAL CO., LTD, Japan) or vehicle (10%
(v/v) DMSO, 10% (v/v) Tween80, 80% (w/v) NaCl) once a day
for 7 days. Compound solutions were kept at ,35uC and injected
i.p. at a dose of 100 ml/g BW (3 mg/ml). BW and food intake were
recorded each day. After 1 week, ten mice for tissue analyses were
euthanized by cervical dislocation; their blood and tissue samples
were recovered and stored at 280uC. Total seventeen mice in two
independent experiments for glucose tolerance test were fasted for
17 h after the final injection of evodiamine or vehicle.
Biochemical analysis
Blood samples were collected from a tail vein and used
immediately to determine the glucose level with a glucometer
(OneTouch Ultra, Johnson & Johnson K.K., Tokyo, Japan).
Insulin levels were measured with serum and commercial assay kits
(Ultrasensitive insulin ELISA, Mercodia, Winston Salem NC,
USA). An i.p. glucose tolerance test (IPGTT) using 1.5 mg
glucose/g BW was done after starvation for 17 h. The blood
glucose level was measured before the injection of glucose at time
zero and at 30, 60 and 120 min later.
Cell culture
3T3-L1 cells (ATCC, CL173, DS Pharma Biomedical Co.,
Osaka, Japan) were grown in Dulbecco’s modified Eagle medium
(DMEM; Wako Pure Chemical, Osaka, Japan) containing 10%
Figure 8. Effect of evodiamine and rosiglitazone on the mTOR-S6K signaling in adipocytes with or without insulin stimulation. After
3T3-L1 pre-adipocytes were differentiated into mature adipocytes, the cells were maintained in DMEM for 4 h and then stimulated by 20 nM insulin,
20 mM evodiamine or 20 mM rosiglitazone alone, or in combination with insulin and evodiamine or rosiglitazone for 30 min. The cell lysates (15–
30 mg protein) were analyzed for phosphorylation of mTOR Ser2448, S6K Thr389, IRS1 Ser636/639, Akt Ser473, ERK Thr202/Tyr204 and AMPK Thr172
by Western blot analysis. Phosphorylation levels were normalized to the total level of each protein. Data are expressed as mean6SEM (n = 3–5).
*p,0.05, **p,0.01, ***p,0.001 vs. control group without stimulation. #p,0.05, ##p,0.01, ###p,0.001 vs. insulin stimulation.
doi:10.1371/journal.pone.0083264.g008
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(v/v) calf serum (BioWest). Adipocyte differentiation was done
essentially as described but with minor modifications [38]. Briefly,
2 days post confluence, the medium was changed to DMEM
containing 10% (v/v) fetal bovine serum (ICN Biomedicals,
Aurora, OH, USA), 10 mg/ml insulin, 1 mM dexamethasone,
0.5 mM 3-isobutyl-1-methylxanthine and 10 mM pioglitazone.
Dexamethasone, 3-isobutyl-1-methylxanthine and pioglitazone
were withdrawn after 2 days of exposure and insulin was
withdrawn after 4 days. On day 6, most of the pre-adipocytes
were differentiated into adipocytes. The cells were maintained in
DMEM for 4 h and then stimulated by 20 nM insulin, 20 mM
evodiamine or 20 mM rosiglitazone (Wako).
Protein analysis
Western blot analysis was done as described with the total tissue
lysates or whole-cell lysates recovered from the WAT or 3T3-L1
adipocytes [39]. The concentration of protein in the lysates was
measured with the BCA protein assay (Pierce Biotechnology,
Rockford, IL, USA). Equal amounts of protein (15–50 mg) were
separated by electrophoresis in SDS/4–20% (w/v) polyacrylamide
gels (Daiichi Pure Chemicals, Tokyo, Japan) and transferred
electrophoretically onto Immobilon polyvinylidene difluoride
membranes (Millipore, Bedford, MA, USA). The membranes
were incubated with specific antibodies against Akt, phospho-
Ser473 Akt, mTOR, phospho-Ser2448 mTOR, IRS1, phospho-
Ser636/639 IRS1, p70S6 kinase, phospho-Thr389 p70S6 kinase,
PDK1, phospho-Ser241 PDK1, Erk1/2, phospho-Thr202/
Tyr204 Erk1/2, AMPK, phospho-Thr172 AMPK (Cell Signaling
Technology, Danvers, MA, USA) or phospho-Tyr612 IRS1/2
(Santa Cruz). After the secondary antibody reaction at 4uC
overnight, specific signals were detected using Immobillon
Western Detection Reagents (Merck Japan, Tokyo). The resulting
images were quantified with NIH Image (version 1.63) software.
Glucose uptake analysis
Glucose uptake into 3T3-L1 adipocytes was evaluated accord-
ing to the method of Saito et al. [40] with minor modification.
After the adipocytes were maintained in DMEM for 6 h, cells
were washed with Krebs Ringer Phosphate Hepes (KRPH) buffer
(20 mM HEPES, 5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2,
136 mM NaCl, 4.7 mM KCl, pH 7.4) containing 2% bovine
alubumin (fatty acid-free, NACALAI TESQUE, INC. KYOTO,
JAPAN) three times and incubated in the KRPH buffer for
40 min. The cells were then stimulated by 20 nM insulin with or
without 20 mM evodiamine for 40 min and with 1 mM 2-Deoxy-
D-glucose (2DG, Sigma-Aldrich, St. Louis, MO, USA) for the last
20 min. Cells were washed with ice-cold phosphate buffered saline
containing 5 mM cytochalasin B (Sigma-Aldrich) three times and
collected in 1 ml of 10 mM Tris-HCl (pH 8.0). After sonication,
the homogenates were heated at 80uC for 15 min and centrifuged
at 15,000 g for 20 min at 4uC. A portion of the resulting
supernatant was diluted 10 times with 10 mM Tris-HCl (pH 8.0)
and analyzed for 2DG6P content by using glucose uptake
colorimetric assay kit (BioVision, Milpitas, CA, USA). The
2DG6P content in each sample was corrected by subtracting the
value derived from the untreated cells without 2DG addition.
Histological analysis
Immediately after removal, tissue pieces were fixed by
immersion at 4uC in 10% (v/v) formaldehyde in neutral buffer
solution (Kishida Chemical), dehydrated, cleared and embedded
in paraffin. Paraffin sections (4-mm thick) were stained with
hematoxylin and eosin. All observations were done with a
fluorescence microscope (Biorevo BZ-9000; Keyence, Tokyo,
Japan). The average cell size of adipocytes in WAT was calculated
by dividing the chosen microscopic area by the total cell number
in the area.
Statistical analysis
Data were expressed as mean6SEM. Differences between
groups were assessed by analysis of variance (ANOVA) or repeated
measure ANOVA. The level of statistically significant difference
was set at p#0.05.
Supporting Information
File S1 Methods S1, Animal experiments using UCP1-knockout
(KO) mice and cell culture experiments using 3T3-L1 pre-
adipocytes. References S1, References for supplementary meth-
ods. Figure S1, Effect of evodiamine on mTOR-S6K signaling in
the RWAT of KK-Ay mice treated with evodiamine. Western blot
analysis of mTOR (A), S6K (B), Akt (C) and IRS1 (D) was done
with tissue lysates (30 mg protein) of retroperitoneal WAT from
KK-Ay mice treated with evodiamine for 7 days. Phosphorylation
levels of mTOR Ser2448, S6K Thr389, Akt Ser473 and IRS1
Ser636/639 were normalized to the total level of each protein.
Figure 9. Effect of evodiamine on AMPK phosphorylation in the WAT, liver and sleletal muscle of mice treated with evodiamine.
Western blot analysis for AMPK were done with tissue lysates (30 mg protein) of IWAT (A), liver (B) and gastrocnemius muscle (C) from the KK-Ay mice
treated with evodiamine for 7 days. Phosphorylation levels of AMPK Thr172 were normalized to its total level. Data are expressed as mean6SEM
(n = 5). *p,0.05, **p,0.01 vs. vehicle group.
doi:10.1371/journal.pone.0083264.g009
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Data are expressed as mean6SEM (n = 5). *p,0.05 vs. vehicle
group. Figure S2, Effect of evodiamine on phosphorylation of
mTOR, Akt and IRS1 in the WAT of obese UCP1-KO mice.
Western blot analysis for mTOR (A), Akt (B) and IRS1 (C) was
done with tissue lysates (50 mg protein) of epididymal WAT from
the UCP1-KO mice fed a high-fat diet with or without evodiamine
for 2 months as described in Supplemental Methods. Phosphor-
ylation levels of mTOR Ser2448, Akt Ser473 and IRS1 Ser636/
639 were normalized to the total level of each protein. Data are
expressed as mean6SEM (n = 4). *p,0.05 vs. control group.
Figure S3, Effect of evodiamine on phosphorylation of mTOR and
UCP1 in the BAT of KK-Ay mice treated with evodiamine.
Western blot analysis for mTOR (A) and UCP1 (B) was done with
tissue lysates (30 mg protein) of BAT from KK-Ay mice treated
with evodiamine for 7 days. Levels of mTOR Ser2448
phosphorylation and UCP1 protein were normalized to the total
mTOR and tubulin levels, respectively. Data are expressed as
mean6SEM (n = 5). Figure S4, Effect of evodiamine on phos-
phorylation of mTOR, S6K, Akt and IRS1 in the gastrocnemius
muscle (GM) of KK-Ay mice treated with evodiamine. Western
blot analysis for mTOR (A), S6K (B), Akt (C) and IRS1 (D) was
done with tissue lysates (30 mg protein) of GM from KK-Ay mice
treated with evodiamine for 7 days. Phosphorylation levels of
mTOR Ser2448, S6K Thr389, Akt Ser473 and IRS1 Ser636/639
were normalized to the total level of each protein. Data are
expressed as mean6SEM (n = 5). Figure S5, Effect of evodiamine
on phosphorylation of ERK, Akt and IRS1 in pre-adipocytes.
3T3-L1 pre-adipocytes were serum-deprived for 4 h and then
treated with 20 mM evodiamine for 1 h and with 20 nM insulin
for the last 10 min. Western blot analysis for ERK, Akt and IRS1
were done with cell lysates (30 mg protein). Figure S6, Measure-
ment of oxygen consumption (VO2) and respiratory quotient (RQ)
in UCP1-KO mice with or without treatment with evodiamine.
VO2 (A) and RQ (B) were measured for 24 h in male mice injected
with vehicle or evodiamine (3 mg/kg BW) at 14:00 h. C, Data on
RQs were analyzed as relative cumulative frequency (PRCF).
Each curve represents 1365 measurements of RQ from three mice
for each group as described in Supplemental Methods. Data are
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